InterventionsHumans

Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies

AHA Scientific Sessions 2025 Abstract

The paper

Xi Tan, Yuanjie Michael Liang, Caichen Zhong,

Lin Xie, Mico Guevarra, Caroline Swift,

Adam de Havenon

Novo Nordisk Inc. · Yale University

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4351008

doi.org/10.1161/circ.152.suppl_3.4351008

SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Drug Design, Development and Therapy · 5 Oct 2026